Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507337-22-00

Acronym

D4191C00137 ROSY-D

Enrollment

Registered

2024-04-10

Start date

2022-06-14

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) in treatment naive patients with epidermal growth factor receptor (EGFR)and anaplastic lymphoma kinase (ALK) wild type tumour pathology, First-line patients with extensive disease (Stage IV) small-cell lung cancer (SCLC)., Locally Advanced, Post-Chemotherapy Urothelial and Non-Urothelial Carcinoma of the Urinary Tract, Unresectable Non-Small Cell Lung Cancer (Stage III)

Brief summary

SAEs reported until 90 days after the last dose of study treatment.

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGMYCOPHENOLATE MOFETIL

DRUGINFLIXIMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
SAEs reported until 90 days after the last dose of study treatment.	—

Countries

Belgium, Bulgaria, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026